Charles River Laboratories International, Inc.
CRL · NYSE
12/28/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,565 | $12,110 | $11,072 | $18,949 |
| - Cash | $195 | $277 | $234 | $245 |
| + Debt | $2,724 | $3,066 | $3,097 | $3,206 |
| Enterprise Value | $12,094 | $14,900 | $13,935 | $21,910 |
| Revenue | $4,050 | $4,129 | $3,976 | $3,540 |
| % Growth | -1.9% | 3.9% | 12.3% | – |
| Gross Profit | $1,332 | $1,503 | $1,463 | $1,335 |
| % Margin | 32.9% | 36.4% | 36.8% | 37.7% |
| EBITDA | $581 | $1,032 | $986 | $820 |
| % Margin | 14.3% | 25% | 24.8% | 23.2% |
| Net Income | $10 | $475 | $486 | $391 |
| % Margin | 0.3% | 11.5% | 12.2% | 11% |
| EPS Diluted | 0.2 | 9.22 | 9.48 | 7.6 |
| % Growth | -97.8% | -2.7% | 24.7% | – |
| Operating Cash Flow | $735 | $684 | $620 | $761 |
| Capital Expenditures | -$233 | -$319 | -$325 | -$229 |
| Free Cash Flow | $502 | $365 | $295 | $532 |